Clinical Trial: Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07698275) titled 'Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted Conditions' on July 07.

Brief Summary: Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x4, replicated, two treatments, four periods, two sequences controlled clinical study

Study Start Date: Jan. 12

Study Type: INTERVENTIONAL

Condition: Bioequivalance

Intervention: DRUG: TAMSULOSIN TEST

Tamsulosin 0.4 mg ER tablet, test

DRUG: OMNIC OCAS REFERENCE

Omnic Ocas, 0.4 mg, ER tablet, Reference

Recruitment Status: COMPLETED

Sponsor: ADIUM

Disclaimer: Curated by HT Syn...